WebJan 15, 2008 · One of the Phase II trials involved 553 obese patients who were tested for 12 weeks. They were divided into groups that received different daily doses of taranabant … WebFeb 25, 2008 · And Vioxx, as I said here at the time, was not, in my opinion, necessarily a bad drug. It and the other COX-2 inhibitors have a real place in the pharmacopeia. The …
The future of endocannabinoid-oriented clinical research after CB
WebTaranabant (N- [ (1S,2S)-3- (4-chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- { [5- (trifluoromethyl)pyridin-2-yl]oxy}propanamide or MK-0364) is an orally active inverse agonist of the cannabinoid 1 (CB-1) receptor that was under development for the management of obesity. Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety. jenga online play
Taranabant - an overview ScienceDirect Topics
Web1Merck & Co., Inc, Whitehouse Station, NJ; 2Currently at FDA, Rockville, MD; 3Cognigen Corporation, Buffalo, NY; 4Currently at Global Alliance for TB Drug Development, New York, NY • Taranabant is a cannabinoid-1 receptor (CB1R) inverse agonist, that was being developed by Merck and Co., Inc. as a potential treatment of obesity[1]. WebJun 1, 2010 · At around the same time, Merck announced the withdrawal of their cb¡-antagonist taranabant from phase ii and iii studies for the indications of smoking cessation and obesity, also due to... WebApr 1, 2008 · Data from a Phase III study of Merck’s taranabant shows obese patients experienced statistically significant weight loss when they took the drug in combination with diet and exercise, the company says. jenga online